Fisher Jumps Into Molecular Dx with Athena Buy, Nanogen Stake; Cardio Assays First, PGx to Follow | GenomeWeb

Fisher Scientific is moving to take a place among molecular diagnostics and pharmacogenomics firms.

The company said last week that it plans to acquire Athena Diagnostics for $283 million in cash and spend $15 million for a 9-percent stake in Nanogen in order to develop molecular and point-of-care diagnostics from the companies' products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.